EYES - Second Sight Medical Products, Inc.

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc. , in a reverse merger transaction.

As of May 29, 2026: spot at $28.01, ATM IV 58.7%, max pain $26.00, net GEX $462.

Sector

Healthcare

Industry

Medical - Devices

Market Cap

$210.0M

Beta

2.56

CEO

Matthew Pfeffer

Employees

15

IPO Date

Nov 19, 2014

Exchange

NASDAQ

What EYES Looks Like to Options Traders Today

IV rank of 0.7% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($462) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.054) prices calls richer than puts, often reflecting upside speculation or squeeze risk.

What This Page Covers

The EYES overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.